EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 183 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,946,751 | -6.1% | 68,620 | -3.2% | 0.00% | -50.0% |
| Q4 2022 | $2,072,553 | +10.0% | 70,905 | -0.5% | 0.00% | +100.0% |
| Q3 2022 | $1,884,000 | -48.5% | 71,289 | -13.3% | 0.00% | -66.7% |
| Q2 2022 | $3,655,000 | -11.2% | 82,259 | -1.1% | 0.00% | 0.0% |
| Q1 2022 | $4,117,000 | -8.0% | 83,195 | -5.3% | 0.00% | 0.0% |
| Q4 2021 | $4,476,000 | -18.6% | 87,897 | -10.9% | 0.00% | -25.0% |
| Q3 2021 | $5,501,000 | +27.3% | 98,616 | -2.3% | 0.00% | +33.3% |
| Q2 2021 | $4,322,000 | -6.4% | 100,986 | -8.7% | 0.00% | 0.0% |
| Q1 2021 | $4,618,000 | -8.5% | 110,639 | +2.1% | 0.00% | -25.0% |
| Q4 2020 | $5,046,000 | +10.7% | 108,353 | +1.0% | 0.00% | 0.0% |
| Q3 2020 | $4,559,000 | +9.8% | 107,331 | +24.0% | 0.00% | 0.0% |
| Q2 2020 | $4,153,000 | +4.0% | 86,550 | -0.3% | 0.00% | 0.0% |
| Q1 2020 | $3,993,000 | -26.1% | 86,799 | -3.5% | 0.00% | -20.0% |
| Q4 2019 | $5,403,000 | +19.7% | 89,930 | +12.7% | 0.01% | +25.0% |
| Q3 2019 | $4,513,000 | -1.9% | 79,770 | -3.5% | 0.00% | 0.0% |
| Q2 2019 | $4,601,000 | +10.0% | 82,639 | -0.2% | 0.00% | 0.0% |
| Q1 2019 | $4,181,000 | +16.2% | 82,801 | -7.3% | 0.00% | 0.0% |
| Q4 2018 | $3,597,000 | -42.3% | 89,289 | -0.7% | 0.00% | -20.0% |
| Q3 2018 | $6,237,000 | +27.1% | 89,958 | +38.7% | 0.01% | 0.0% |
| Q2 2018 | $4,906,000 | +26.0% | 64,838 | -12.2% | 0.01% | +25.0% |
| Q1 2018 | $3,893,000 | +2.0% | 73,885 | +3.4% | 0.00% | 0.0% |
| Q4 2017 | $3,817,000 | -12.3% | 71,449 | -2.1% | 0.00% | 0.0% |
| Q3 2017 | $4,351,000 | -18.9% | 72,953 | +7.3% | 0.00% | -20.0% |
| Q2 2017 | $5,364,000 | +4.3% | 67,990 | +9.6% | 0.01% | -16.7% |
| Q1 2017 | $5,145,000 | +11.5% | 62,036 | +6.7% | 0.01% | 0.0% |
| Q4 2016 | $4,614,000 | +13.4% | 58,157 | +0.0% | 0.01% | +20.0% |
| Q3 2016 | $4,070,000 | – | 58,138 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
| Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
| Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
| U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
| Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
| CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
| ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
| Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
| GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |